undefined undefined
NaN.000
NaN.00%
Leerink Partners analyst Mani Foroohar downgrades CureVac (NASDAQ:CVAC) from Outperform to Market Perform and lowers the price target from $12 to $4.
04-25 21:12
Curevac N.V. (CVAC) has released an update. CureVac N.V., a biopharmaceutical c...
04-25 05:30
Curevac N.V. (CVAC) has released an update. CureVac N.V., a leader in mRNA tech...
04-25 05:29
Curevac N.V. (CVAC) has released an update. CureVac N.V., a leading mRNA biopha...
04-25 05:28
CureVac BV press release (NASDAQ:CVAC): Q4 pre-tax loss was €86.5 million and €260.0 million for the three and twelve months ended December 31, 2023, compared to €128.7 million and €249.2 million in t...
04-24 19:30
CureVac BV (NASDAQ:CVAC) is scheduled to announce FQ4 earnings results on Wednesday, April 24th, before market open. The consensus EPS Estimate is -$0.15 and the consensus Revenue Estimate is $31.52M....
04-24 02:08
Gainers: Vanda Pharmaceuticals (VNDA) +7%. Sutro Biopharma (STRO) +5%. CureVac (CVAC) +5%. CorMedix (CRMD) +4%. Bank OZK (OZK) +4%. Losers: Omega Therapeutics (OMGA) -4%. Leslie's (LESL) -3%. Signa...
04-18 05:01
GSK (NYSE:GSK) said a long-term followup study showed that its top-selling shingles vaccine, Shingrix, had a 79.7% efficacy rate six to 11 years after vaccination in people aged 50 and older. Results ...
04-18 01:26
Curevac N.V. (CVAC) has released an update. CureVac N.V., a leader in mRNA tech...
04-17 05:27
CureVac (NASDAQ:CVAC) and the University of Texas MD Anderson Cancer Center announced a co-development and licensing pact to develop novel, off-the-shelf, mRNA-based cancer vaccines for selected hemat...
04-16 19:59